Out-Law News 2 min. read
30 Sep 2014, 4:11 pm
Guido Rasi confirmed to the European Parliament that the EMA's management board will approve the new policy on Thursday, according to a report by EU news website euractiv.com. A spokesperson for the EMA confirmed to Out-Law.com that the body will release details of the new policy after the management board's meeting either on Thursday afternoon or Friday.
"Our new policy will spell out clearly what will be the principles to gain access," Rasi said, according to the euractiv.com report. "The decisions, however, will always be taken by the EMA. Next Thursday, our management board will approve this new version of the policy. That should give us, from the start of 2015, the possibility to start to actively make data available. By 2016, we should have the first clinical trials data available."
Paul Ranson, a specialist in the regulation of clinical trials at Pinsent Masons, the law firm behind Out-Law.com, said that the EMA is expected to announce that it will, as a first step, make Clinical Study Reports (CSRs) available after product assessment subject to the redaction of identified commercially confidential information. CSRs are documents that contain all the details of a clinical trial that are submitted to regulators by a company seeking authorisation to market a new product.
The EMA previously announced that its new policy would not address issues concerning the disclosure of individual patient data (IPD) generated from clinical trials.
Ranson said that the EMA is still engaged with stakeholders in discussing what conditions to impose on access to IPD. However, he said many companies have already adopted their own policies and allow restricted access to IPD using a gatekeeper model, which is where a trusted third party control access to the data and impose privacy safeguards. Some, like GSK, have created their own 'safe havens' where certain data can be viewed but not extracted, whilst others, such as Bristol Myers Squibb, are making the data available through a collaborative safe haven, Ranson said.
"An important consideration for companies is what is said about data reuse and data sharing in the consent form signed by participants," Ranson said. "This is likely to be more of an issue for past trials as data sharing and reuse can be addressed in the consent forms for new trials."
Earlier this year the European Ombudsman Emma O'Reilly criticised EMA draft plans which she said would, if introduced, allow clinical trials data only to be accessible on screen using an interface provided by the EMA.
O'Reilly claimed further "wide restrictions" would apply to how the data could be used, something which the EMA denied at the time. It said it intended to make clinical trial data publicly accessible online and that restrictions it was considering were designed to prevent those who access the information using it for commercial gain.
Competing interests surround the issue of whether and to what extent clinical trial data should be made publically available. Many stakeholders believe that medical research would be enhanced if there was full transparency from the results of clinical trials.
However, others believe that at least an element of confidentiality is required to protect the significant investments drug companies make in carrying out clinical trials and developing new drugs. They believe rival companies should not be able to piggy-back on their investment and launch new products onto market at their expense.
Expert in life sciences Helen Cline of Pinsent Masons said: "There is a whole spectrum of benefits that could arise from making the clinical trial process and clinical trial data more transparent from improving the efficiency of drug discovery to the public health benefits.”
Earlier this year, the Council of Ministers and the European Parliament voted in favour of a new Clinical Trials Regulation which will require pharmaceutical companies and other medical researchers to post results of all their European clinical trials on a publicly-accessible database.